China approves new COVID vaccine for clinical trials
2021-04-10 23:55
BEIJING  A new COVID vaccine developed by Chinas Sinopharm has recently been approved for clinical trials.The new recombinant COVID vaccine, developed by the National Vaccine  Serum Institute, a RD center of Sinopharms bioscience subsidiary the China National Biotec Group CNBG, got approval from the National Medical Products Administration on Friday, the CNBG said on its official Weibo account on Saturday.The vaccine is based on the structural features of the receptor binding domain RBD on the virus spike protein Sprotein. It uses genetic engineering to grow harmless copies of the virus Sprotein to induce neutralizing antibodies.The company said that recombinant vaccine technology is mature and suitable for largescale production. The production does not require facilities with high biosafety levels since the process does not involve live viruses.The recombinant vaccine is the companys third COVID vaccine. Last December, an inactivated vaccine developed by the Beijing Biological Products Institute Co., Ltd. under CNBG became the first Chinese COVID vaccine to have conditional marketing authorization.In February, another inactivated vaccine from the Wuhan Institute of Biological Products, a CNBG affiliate, was allowed to enter the market on a conditional basis.More than . million doses of COVID vaccines had been administered across China as of Friday, the National Health Commission said Saturday.